A Phase I Study of the Anti-Breast Cancer Immunotoxin 260F9 Mab-rRA Given by Intravenous Continuous Infusion

  • Bruce J. Gould
  • Michael J. Borowitz
  • Eric S. Groves
  • Arthur E. Frankel


Immunotoxins(IT) are biologically derived compounds that are under development as anti-neoplastic agents(1`. An immunotoxin consists of a carrier protein that guides a covalently linked toxin to a tumor cell. Monoclonal antibodies which have specificity for tumor cell. Monoclonal antibodies serve as carrier molecules. Plant or bacteria derived toxins such as ricin, pseudomonas exotoxin, and diphtheria toxin are commonly used cellular poisons(2).


Chronic Lymphocytic Leukemia Inhibit Protein Synthesis Diphtheria Toxin Chest Wall Tumor Refractory Chronic Lymphocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Frankel A, Houston L, Issell, B. Prospects for immunotoxin therapy in cancer.Ann. Rev. Med. 37: 125–142 1986.PubMedCrossRefGoogle Scholar
  2. 2.
    Pastan I, Willingham M, Fitzgerald J. Immunotoxins.Cell 47: 641–648 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    Olnes S, Sandvig K. How protein toxins enter and kill cells. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 39–74 1988.CrossRefGoogle Scholar
  4. 4.
    Robertus J. D. Toxin structure. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 11–24 1988.CrossRefGoogle Scholar
  5. 5.
    Bjorn M, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins.Cancer Res. 45: 1214–1221 1985.PubMedGoogle Scholar
  6. 6.
    Data on file at the Cetus Corporation.Google Scholar
  7. 7.
    Hertler A, Schlossman D, Borowitz M, Blythnman H, Caselas P, Frankel A. Anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.Inter. J. of Cancer 43: 215–219.Google Scholar
  8. 8.
    Blakey D, Thorpe P. Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 457–474 1988.CrossRefGoogle Scholar
  9. 9.
    Spitler L, del Rio M, Khentigan A, Wedel N, Brophy N, Miller L, Harkonen W, Rosendorf L, Lee H, Mischak R, Kawahata R, Stoudemire J, Fradkin L, Bautista E, Scannon P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibodyricin A chain immunotoxin.Cancer Res. 47: 1717–1723 1987.PubMedGoogle Scholar
  10. 10.
    Hertler A, Schlossman D, Borowitz M, Laurent G, Jansen F, Schmidt C, Frankel A. A phase I study of T101 ricin A chain immunotoxin in refractory chronic lymphocytic leukemia J. of Biological Response Modifiers 7: 97–113 1988.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Bruce J. Gould
    • 1
  • Michael J. Borowitz
    • 2
  • Eric S. Groves
    • 3
  • Arthur E. Frankel
    • 1
  1. 1.Department of Hematology/OncologyDuke University Medical CenterDurhamUSA
  2. 2.Department of PathologyDuke University Medical CenterDurhamUSA
  3. 3.Cetus CorporationEmeryvilleUSA

Personalised recommendations